

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Cyclin D3 (DCS22) Mouse mAb

RRID:AB_2070801

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2936, RRID:AB_2070801

Antibody Information

URL: http://antibodyregistry.org/AB_2070801

Proper Citation: Cell Signaling Technology Cat# 2936, RRID:AB_2070801

Target Antigen: Cyclin D3 (DCS22) Mouse mAb

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P. Consolidation on 11/2018: AB_10698739, AB_10841292, AB_2070801, AB_2314272.

Antibody Name: Cyclin D3 (DCS22) Mouse mAb

Description: This monoclonal targets Cyclin D3 (DCS22) Mouse mAb

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_2070801

Vendor: Cell Signaling Technology

Catalog Number: 2936

Record Creation Time: 20250820T011745+0000

Record Last Update: 20250820T103304+0000

Ratings and Alerts

- Used for immunocytochemistry by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for Cyclin D3 (DCS22) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mahmoud A, et al. (2025) Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. bioRxiv : the preprint server for biology.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. bioRxiv : the preprint server for biology.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Tang J, et al. (2025) Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. Cell chemical biology, 32(2), 352.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Cell reports. Medicine, 6(1), 101890.

Ogawa A, et al. (2025) SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. Molecular cell, 85(5), 894.

Wang Q, et al. (2025) Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development. eLife, 13.

Ullrich V, et al. (2024) KDM5B predicts temozolomide-resistant subclones in glioblastoma. iScience, 27(1), 108596.

Zhou H, et al. (2024) Neddylation and Its Target Cullin 3 Are Essential for Adipocyte Differentiation. Cells, 13(19).

Shin S, et al. (2023) mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. Cell reports, 42(8), 112868.

Golkowski M, et al. (2023) Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. Molecular cell, 83(5), 803.

Arora M, et al. (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. *Cell*, 186(12), 2628.

Takahashi K, et al. (2022) TGF- β generates a population of cancer cells residing in G1 phase with high motility and metastatic potential via KRTAP2-3. *Cell reports*, 40(13), 111411.

Tan J, et al. (2022) Moderate heart rate reduction promotes cardiac regeneration through stimulation of the metabolic pattern switch. *Cell reports*, 38(10), 110468.

Fischer N, et al. (2021) A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy. *Investigational new drugs*, 39(4), 914.

Zhao R, et al. (2020) Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase. *British journal of pharmacology*, 177(10), 2303.

Ramezani-Rad P, et al. (2020) Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells. *Cell reports*, 33(7), 108403.

Xiong L, et al. (2020) LncRNA-Malat1 is Involved in Lipotoxicity-Induced β -cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptp1. *Endocrinology*, 161(7).

Xiao B, et al. (2020) Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. *Cell reports*, 31(4), 107571.

Au CC, et al. (2020) Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. *eLife*, 9.